Telomere length variation in biliary tract metaplasia, dysplasia, and carcinoma

Modern Pathology

Volumn 19, Issue 6, 2006, Pages 772-779

  Hansel, Donna E ^a   Meeker, Alan K ^a   Hicks, Jessica ^a   De Marzo, Angelo M ^a   Lillemoe, Keith D ^a,c   Schulick, Richard ^a   Hruban, Ralph H ^a   Maitra, Anirban ^a   Argani, Pedram ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Bile duct; Carcinoma; Dysplasia; Gallbladder; Metaplasia; Telomere

Indexed keywords

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER DISEASE; GALLBLADDER EPITHELIUM; HUMAN; HUMAN TISSUE; INFLAMMATION; METAPLASIA; PRIORITY JOURNAL; TELOMERE; VALIDATION PROCESS;

BILIARY TRACT NEOPLASMS; CARCINOMA IN SITU; DNA, NEOPLASM; EPITHELIUM; GALLBLADDER; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METAPLASIA; PRECANCEROUS CONDITIONS; TELOMERE;

EID: 33646888178     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800591     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 1998;48:6-29.
2. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364.
3. de Groen PC, Gores GJ, LaRusso NF, et al. Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
4. Duarte I, Llanos O, Domke H, et al. Metaplasia and precursor lesions of gallbladder carcinoma. Frequency, distribution, and probability of detection in routine histologic samples. Cancer 1993;72:1878-1884.
5. Kamel D, Paakko P, Nuorva K, et al. p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 1993;170:67-72.
6. Tanno S, Obara T, Fujii T, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreatico-biliary ductal union. Cancer 1998;83:267-275.
7. Wistuba II, Sugio K, Hung J, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 1995;55:2511-2515.
8. Wistuba II, Albores-Saavedra J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999;6:237-244.
9. Itoi T, Watanabe H, Ajioka Y, et al. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996;46:333-340.
10. Blasco MA, Lee HW, Rizen M, et al. Mouse models for the study of telomerase. Ciba Found Symp 1997;211:160-170; discussion 70-76.
11. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645.
12. Meeker AK, Gage WR, Hicks JL, et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am J Pathol 2002;160:1259-1268.
13. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002;161:1541-1547.
14. Meeker AK, Hicks JL, Platz EA, et al. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002;62:6405-6409.
15. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002;21:619-626.
16. Kim SH, Kaminker P, Campisi J. Telomeres, aging and cancer: in search of a happy ending. Oncogene 2002;21:503-511.
17. Blackburn EH. Telomere states and cell fates. Nature 2000;408:53-56.
18. Gasser SM. A sense of the end. Science 2000;288:1377-1379.
19. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
20. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-791.
21. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the Gallbladder, Extrahepatic Bile Ducts, and Ampulla of Vater, Atlas of Tumor Pathology, 3rd series, Fascicle 27. Armed Forces Institute of Pathology: Washington, DC, p 39, 51.
22. Momoi H, Okabe H, Kamikawa T, et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res 2001;7:2648-2655.
23. Wistuba II, Tang M, Maitra A, et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001;61:3795-3800.
24. Shiraishi K, Okita K, Kusano N, et al. A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 2001;60:151-161.
25. Rijken AM, Hu J, Perlman EJ, et al. Genomic alterations in distal bile duct carcinoma by comparative genomic hybridization and karyotype analysis. Genes Chromosomes Cancer 1999;26:185-191.
26. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci 2002;27:339-344.
27. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995;92:4818-4822.
28. Holt SE, Wright WE, Shay JW. Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997;33:761-766.
29. Chiu CP, Harley CB. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc Soc Exp Biol Med 1997;214:99-106.
30. Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases mutation rate and genomic instability. Cell 2001;106:275-286.
31. de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990;10:518-527.
32. Hastie ND, Dempster M, Dunlop MG, et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1991;350:866-868.
33. Hoang MP, Murakata LA, Padilla-Rodriguez AL, et al. Metaplastic lesions of the extrahepatic bile ducts: a morphologic and immunohistochemical study. Mod Pathol 2001;14:1119-1125.
34. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
35. Shay JW, Wright WE. Ageing and cancer: the telomere and telomerase connection. Novartis Found Symp 2001;235:116-125; discussion 25-29, 46-49.
36. Parwani A, Geradts J, Caspers E, et al. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol 2003;16:299-308.
37. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-1274.
38. Le S, Moore JK, Haber JE, et al. RAD50 and RAD51 define two pathways that collaborate to maintain telomeres in the absence of telomerase. Genetics 1999;152:143-152.